SOURCE: Oragenics, Inc.

September 05, 2007 09:56 ET

Oragenics' Lead Antibiotic Effectively Kills Vancomycin-Resistant Bacteria

ALACHUA, FL--(Marketwire - September 5, 2007) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company, announced today laboratory results from a Tier 3 spectrum of activity study, conducted at an independent testing facility, which demonstrated that its lead antibiotic candidate, MU1140™, was effective at clinically relevant doses in killing pathogenic bacteria that are resistant to a variety of antibiotics, including all vancomycin-resistant strains of enterococci and Staphylococcus aureus in the Tier 3 Gram-positive bacterial panel. Vancomycin, approved by the FDA in 1958, is still considered the drug of "last resort" and is used for the treatment of serious, life-threatening infections which have not responded to other antibiotics.

MU1140™ was previously reported to be effective in a Staph. aureus infected mouse model system, and has recently displayed protection when administered by intravenous injection to rats infected intraperitoneally with sixty times the lethal dose of this pathogen. The results of these two animal sepsis studies suggest that MU1140 can also act against bacteria in a living animal. Maximum tolerated dose studies in the rat model confirm that a toxic dose of MU1140 appears to be well above the observed therapeutic dose for this antibiotic.

"With the continued emergence of superbugs that are resistant to our strongest antibiotics, now including vancomycin, there is an on-going effort in the pharmaceutical industry to identify and develop new antibiotics," stated Dr. Robert Zahradnik, Oragenics' President and CEO. "MU1140™ represents a major new class of antibiotics and one day it could become a clinically useful tool against those bacteria responsible for life-threatening multi-drug resistant hospital and community acquired infections." In parallel with the MU1140 studies, Oragenics' proprietary DPOLT™ technology platform is currently completing proof-of-principle studies, and could represent a means of cost-effectively manufacturing MU1140, as well as the potential for producing sufficient quantities of the approximately fifty other members of the lantibiotic family for preclinical evaluation of their potential usefulness as therapeutic agents for treating various infections.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and weight loss. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact Information